FMPV 3
Alternative Names: FMPV-3Latest Information Update: 19 Dec 2022
At a glance
- Originator Hubro Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hereditary nonpolyposis colorectal cancer
Most Recent Events
- 12 Dec 2022 Preclinical trials in Cancer in Norway (Parenteral) (Hubro Therapeutics pipeline, December 2022)
- 12 Dec 2022 Preclinical trials in Hereditary nonpolyposis colorectal cancer (Prevention) in Norway (Parenteral) (Hubro Therapeutics pipeline, December 2022)